Radioimmunotherapy vs Chemoimmunotherapy for Non-Small Cell Lung Cancer

Overseen By Julia Muuse

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Weill Medical College of Cornell University

Must not be taking: Immunosuppressants, Live vaccines

Disqualifiers: Autoimmune disorders, Uncontrolled illness, HIV, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 4 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 13

112 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial evaluates two treatments for stages IB, II, and III (N2) Non-Small Cell Lung Cancer (NSCLC) to determine if adding Cemiplimab (an immunotherapy drug) to either chemotherapy or stereotactic body radiation therapy (a precise form of radiation) is effective before surgery. Participants will receive either Cemiplimab with chemotherapy or Cemiplimab with targeted radiation, followed by Cemiplimab alone after surgery. Suitable candidates for this trial include those diagnosed with NSCLC at the specified stages who have not received prior lung cancer therapy. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

Do I need to stop my current medications to join the trial?

The trial does not specify if you need to stop taking your current medications. However, you cannot use immunosuppressive medications within 14 days before starting the trial, except for certain types like inhaled or topical steroids. It's best to discuss your specific medications with the trial team.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that cemiplimab, when combined with platinum-based chemotherapy, is generally well-tolerated. Studies have demonstrated that the FDA has approved this combination for treating non-small cell lung cancer, indicating its safety for this use. However, like all treatments, side effects can occur, ranging from mild to more serious.

Research supports the safety and effectiveness of combining cemiplimab with SBRT (a type of targeted radiation therapy) in treating lung cancer. This combination uses both the immune system and precise radiation to better target cancer cells.

While both treatment options have shown promise, they may cause side effects, which can differ among patients. Discussing potential risks and benefits with healthcare providers is important before joining a trial. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about these treatments because they combine cemiplimab, an innovative immunotherapy drug, with traditional cancer treatments to boost effectiveness against non-small cell lung cancer. Unlike the typical chemotherapy regimens, cemiplimab is an immune checkpoint inhibitor that helps the body's immune system recognize and attack cancer cells more effectively. In one arm of the study, cemiplimab is paired with SBRT, a precise form of radiation therapy, which potentially enhances the immune response and targets the tumor with precision. This multi-faceted approach could lead to improved outcomes by not only shrinking tumors before surgery but also maintaining long-term control of cancer growth after surgery.

What evidence suggests that this trial's treatments could be effective for Non-Small Cell Lung Cancer?

This trial will compare two treatment approaches for non-small cell lung cancer (NSCLC). In one arm, participants will receive cemiplimab with chemotherapy. Research has shown that cemiplimab, when combined with chemotherapy, can significantly improve survival rates for people with advanced NSCLC. Studies have found that this combination more than doubles the chance of living for five years compared to some other treatments. Additionally, the FDA has approved cemiplimab for use with platinum-based chemotherapy for NSCLC, highlighting its effectiveness.

In the other arm, participants will receive cemiplimab combined with stereotactic body radiation therapy (SBRT). Early indications suggest that SBRT can be highly effective when paired with immunotherapy like cemiplimab. SBRT is a targeted form of radiation that aims to destroy cancer cells while protecting healthy tissue. This combination is under study because it shows promise in improving treatment outcomes for NSCLC. ^{6 7 8 9 10}

Who Is on the Research Team?

Nasser K Altorki, MD

Principal Investigator

Weill Medical College of Cornell University

Are You a Good Fit for This Trial?

This trial is for individuals with stages IB, II, and III (N2) Non-Small Cell Lung Cancer who are planning to have surgery. Participants must be fit for both chemotherapy and immunotherapy. They cannot join if they've had previous treatments for NSCLC or have certain medical conditions that the study outlines.

Inclusion Criteria

Measurable disease, as defined by RECIST v1.1.

WOCBP must have a negative serum (beta-hCG) at screening.

WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the entire trial and until 6 months after last treatment.

Exclusion Criteria

I do not have HIV, hepatitis B, or hepatitis C.

I have a lung condition treated with high-dose steroids.

I have had a stem cell or organ transplant in the past.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Neoadjuvant Treatment

Participants receive Cemiplimab with chemotherapy or Cemiplimab with SBRT before surgery

9-13 weeks

Every 3 weeks for up to 3 doses

Surgery

Surgical resection of lung cancer

1 week

1 visit (in-person)

Adjuvant Treatment

Participants receive Cemiplimab post-surgery for one year

1 year

Every 3 weeks for 4 treatments, then every 6 weeks for 11 treatments

Follow-up

Participants are monitored for safety and effectiveness after treatment

5 years

Every 6 months for 3 years, then yearly for years 4-5

What Are the Treatments Tested in This Trial?

Interventions

• Cemiplimab
• Platinum-based Chemotherapy
• Stereotactic Body Radiation Therapy

Trial Overview The trial tests two pre-surgery treatments: Cemiplimab combined with platinum-based chemotherapy (Arm A), or Cemiplimab with stereotactic body radiation therapy (SBRT) (Arm B). After surgery, participants in both groups will continue to receive Cemiplimab for one year.

How Is the Trial Designed?

Group I: Cemiplimab with chemotherapy (Arm A) Experimental Treatment 2 Interventions

Before lung cancer surgery: 1. Cemiplimab 350 mg intravenously every 3 weeks up to 3 cycles. 2. Platinum-based chemotherapy intravenously every 3 weeks up to 3 cycles. After lung cancer surgery, cemiplimab 350 mg intravenously every 3 weeks for 4 treatments followed by 700 mg every 6 weeks for one year (11 treatments).

Group II: Cemiplimab with SBRT (Arm B) Experimental Treatment 2 Interventions

Before lung cancer surgery: 1. Cemiplimab 350 mg intravenously every 3 weeks up to 3 cycles. 2. SBRT on days 1, 2, and 3. After lung cancer surgery, cemiplimab 350 mg intravenously every 3 weeks for 4 treatments followed by 700 mg every 6 weeks for one year (11 treatments).

Cemiplimab is already approved in European Union, United States, Canada, Brazil for the following indications:

Approved in European Union as Libtayo for:

• Cutaneous squamous cell carcinoma (CSCC)
• Non-small cell lung cancer (NSCLC)

Approved in United States as Libtayo for:

• Cutaneous squamous cell carcinoma (CSCC)
• Basal cell carcinoma (BCC)
• Non-small cell lung cancer (NSCLC)

Approved in Canada as Libtayo for:

• Cutaneous squamous cell carcinoma (CSCC)
• Non-small cell lung cancer (NSCLC)

Approved in Brazil as Libtayo for:

• Cutaneous squamous cell carcinoma (CSCC)

Who Is Running the Clinical Trial?

Weill Medical College of Cornell University

Lead Sponsor

Trials

1,103

Recruited

1,157,000+

Regeneron Pharmaceuticals

Industry Sponsor

Trials

690

Recruited

948,000+

Founded

1988

Headquarters

Tarrytown, USA

Known For

Precision medicine

Top Products

Dupixent, EYLEA, Libtayo, Praluent

Leonard Schleifer

Regeneron Pharmaceuticals

Chief Executive Officer since 1988

MD and PhD in Medicine

George Yancopoulos

Regeneron Pharmaceuticals

Chief Medical Officer since 1997

MD from Harvard Medical School

Published Research Related to This Trial

Cemiplimab, administered as monotherapy or in combination with hypofractionated radiation therapy, showed a 10% objective response rate in patients with recurrent or metastatic cervical cancer, particularly in those with squamous histology, indicating its potential efficacy in this subgroup.

The most common side effects were diarrhea, fatigue, and hypokalemia, affecting 35%, 25%, and 25% of patients respectively, suggesting that while cemiplimab has anti-tumor activity, it also has a manageable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. Rischin, D., Gil-Martin, M., González-Martin, A., et al.[2021]

The updated population pharmacokinetic model for cemiplimab, based on data from 1062 patients, demonstrated improved stability and robustness, successfully validating its pharmacokinetics in patients with recurrent or metastatic cervical cancer.

Despite the improved model, the analysis revealed no significant exposure-response relationships for efficacy (overall survival, progression-free survival, duration of response, objective response rate) or safety (immune-related adverse events), indicating that higher drug exposure did not correlate with better outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer. Nguyen, JH., Epling, D., Dolphin, N., et al.[2023]

At 35 months of follow-up, patients with advanced non-small-cell lung cancer and high PD-L1 expression treated with cemiplimab had a median overall survival of 26.1 months, significantly better than the 13.3 months for those receiving chemotherapy, indicating a strong survival benefit from cemiplimab.

The addition of chemotherapy to cemiplimab after disease progression resulted in a median overall survival of 15.1 months, suggesting that this combination could be an effective second-line treatment option for patients with advanced non-small-cell lung cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Özgüroğlu, M., Kilickap, S., Sezer, A., et al.[2023]

Cemiplimab-rwlc is a newly approved PD-1/L1 inhibitor for first-line treatment of metastatic non-small cell lung cancer (NSCLC) without EGFR or ALK mutations, either alone or with chemotherapy.

This review highlights the differences in patient populations studied for cemiplimab compared to other treatments, emphasizing its role in expanding options for NSCLC patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations. Ahn, J., Nagasaka, M.[2023]

In a subanalysis of the KEYNOTE-024 study involving 40 Japanese patients with untreated metastatic non-small-cell lung cancer, pembrolizumab significantly improved progression-free survival (HR 0.25) and overall survival (HR 0.39) compared to chemotherapy.

Both treatment groups experienced high rates of treatment-related adverse events (100% for pembrolizumab and 95% for chemotherapy), but the safety profile was manageable, with a notable occurrence of immune-mediated adverse events in 52% of pembrolizumab patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. Satouchi, M., Nosaki, K., Takahashi, T., et al.[2021]

In a study of 44,498 patients with stage IV non-small-cell lung cancer (NSCLC), stereotactic radiotherapy (SRT) was associated with improved overall survival (OS), showing a hazard ratio of 0.78, indicating a significant benefit regardless of the type of systemic treatment used.

The combination of SRT and immunotherapy showed promising results, with patients receiving SRT having a median OS of 18.2 months compared to 14.3 months for those on chemotherapy, suggesting that SRT may enhance the effectiveness of immunotherapy and warrants further investigation in randomized trials.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis. Foster, CC., Sher, DJ., Rusthoven, CG., et al.[2020]

Immunotherapy and targeted biologics have significantly improved survival rates for patients with non-small cell lung cancer (NSCLC), especially when combined with standard treatments like surgery and radiotherapy.

Radiotherapy not only enhances the effectiveness of immunotherapy on treated tumors but can also trigger immune responses in untreated distant tumors, suggesting a synergistic approach to treating both early-stage and metastatic NSCLC.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancer-A Stimulating Partnership. Dams, RV., Yuan, Y., Robinson, CG., et al.[2021]

Cemiplimab-rwlc (Libtayo) is an FDA-approved immunotherapy for advanced cutaneous squamous cell carcinoma (CSCC) that works by blocking the PD-1 receptor, enhancing the immune system's ability to fight tumors.

Clinical trials have shown that cemiplimab is effective in treating CSCC, although common side effects and safety issues were noted, highlighting the need for ongoing research to improve treatment outcomes and reduce toxicity.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Ahmed, SR., Petersen, E., Patel, R., et al.[2019]

Recent advancements in radiotherapy for lung cancer include various administration methods, such as hyperfractionated and accelerated radiotherapy, which aim to improve treatment efficacy while minimizing damage to healthy tissues.

The use of radiosensitizing agents, like 5-fluorouracil and platinum salts, alongside radiotherapy has shown promise in enhancing treatment outcomes for both non-small-cell and small-cell lung cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[New administration modalities for radiotherapy in lung cancer]. Touboul, E., Deniaud-Alexandre, E., Pereira, R., et al.[2018]

Immune checkpoint inhibitors have significantly improved survival rates in many patients with non-small cell lung cancer (NSCLC) and generally have a good safety profile, but not all patients respond positively to these treatments.

Combination strategies involving chemotherapy or radiotherapy with immunotherapy are being explored to enhance treatment efficacy, as some patients may experience accelerated tumor progression with PD-1 or PD-L1 inhibitors.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? Lazzari, C., Karachaliou, N., Bulotta, A., et al.[2022]

Atezolizumab, cemiplimab, and pembrolizumab are established as standard first-line immunotherapy options for patients with advanced non-small cell lung cancer (NSCLC) who have high PD-L1 expression (≥50%).

The consensus among 25 Spanish lung cancer experts indicates that these therapies can be tailored to specific patient subgroups, enhancing treatment decision-making based on differences observed in pivotal clinical trials.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Isla, D., Sánchez, A., Casal, J., et al.[2023]

In a phase 3 study involving 710 patients with advanced non-small-cell lung cancer and high PD-L1 expression, cemiplimab significantly improved overall survival (not reached) and progression-free survival (8.2 months) compared to chemotherapy (14.2 months).

Cemiplimab also demonstrated a better safety profile, with fewer grade 3-4 treatment-emergent adverse events (28%) compared to chemotherapy (39%), making it a promising first-line treatment option for this patient group.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Sezer, A., Kilickap, S., Gümüş, M., et al.[2022]

Cisplatin combined with either a vinca alkaloid or etoposide is highly effective in reducing mortality for patients with non-small cell lung cancer, as shown in meta-analyses comparing chemotherapy to supportive care.

Recent studies indicate that combining cisplatin-based chemotherapy with new agents and radiotherapy can significantly prolong survival and improve outcomes for patients with locally advanced non-small cell lung cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Chemotherapy for non-small cell lung cancer]. Shinkai, T., Saijo, N.[2018]

Citations

1. clinicaltrials.gov clinicaltrials.gov/study/nct06623656

Study Details | nct06623656 | Preoperative ... The goal of this clinical trial is to learn if Cemiplimab with chemotherapy or Cemiplimab with stereotactic body radiation therapy (SBRT) works as treatment ...

2. jamanetwork.com jamanetwork.com/journals/jamaoncology/fullarticle/2809582

Individualized Stereotactic Ablative Radiotherapy for Lung ... The findings of this study suggest that an individualized dosing regimen, including doses lower than those routinely administered, is associated with excellent ...

3. targetedonc.com targetedonc.com/view/cemiplimab-plus-chemo-shows-5-year-nsclc-survival-benefit

Cemiplimab Plus Chemo Shows 5-Year NSCLC Survival ... New 5-year data reveals cemiplimab plus chemotherapy significantly enhances survival rates for advanced non-small cell lung cancer patients.

4. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC10511897/

Combining stereotactic body radiotherapy with ... Here, we review the current clinical evidence supporting the combination of SBRT with immunotherapy in the treatment of metastatic NSCLC.

5. sciencedirect.com sciencedirect.com/science/article/pii/S1043661824004109

Targeted and cytotoxic inhibitors used in the treatment of ... Stereotactic body radiation therapy is a noninvasive alternative to surgery and can be more effective than conventional radiation therapy because it is more ...

6. newsroom.regeneron.com newsroom.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-plus-chemotherapy-results-five-years

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five ... Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall ...

7. fda.gov fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-combination-platinum-based-chemotherapy-non-small-cell-lung-cancer

FDA approves cemiplimab-rwlc in combination with ... FDA approves cemiplimab-rwlc in combination with platinum-based chemotherapy for non-small cell lung cancer. Resources for Information ...

8. clinicaltrials.gov clinicaltrials.gov/study/NCT03088540

NCT03088540 | Study of REGN 2810 Compared to ... The key secondary objective of the study is to compare the objective response rate (ORR) of cemiplimab versus platinum-based chemotherapies.

9. ncbi.nlm.nih.gov ncbi.nlm.nih.gov/books/NBK604820/

Cemiplimab (Libtayo) - NCBI Bookshelf - NIH Cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC)

10. nature.com nature.com/articles/s41591-022-01977-y

Cemiplimab plus chemotherapy versus ... A double-blind, placebo-controlled, phase 3 study, examined cemiplimab plus platinum-doublet chemotherapy as first-line treatment for aNSCLC.